Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation

Can-Fite BioPharma reported that a patient experienced resolution of ascites and regression of esophageal varices, remaining clinically stable for approximately 28 months before a successful liver transplantation. The limited clinical update is favorable for the company’s liver-disease program, but the article provides no broader trial data, financial metrics, or regulatory milestones.